Published on March 8, 2005 at 3:38 PM
ALDA Pharmaceuticals has filed national patent applications in the United States, Canada and Singapore for the formulation and production of Viralex.
Last April, ALDA received a favourable international review of the patent application for the company’s proprietary infection control technology, including Viralex with T36, from the European Patent Office. Passing the international review is an important step in the process and allows the company to file patent applications in those countries that have attractive market potential.
Dr.Terrance Owen, President and CEO, states, “Patent protection for our technology is a critical component of our business plan and a very valuable asset for a company like ALDA. Patent protection signifies that our technology is sound and is absolutely essential to attract joint venture partners and licensees for many of our planned products.”
A number of new patent applications covering additional T36 products are currently in progress and are expected to significantly broaden the intellectual property base of the company.
http://www.aldacorp.com